Jaguar Health, Inc. (JAGX): Nasdaq/NYSE listing notice — Nasdaq grants Jaguar Health additional 180-day grace period to regain $1.00 bid price compliance

Jaguar Health, Inc.

Nasdaq extended compliance deadline to May 6, 2024; company must close at $1.00+ for 10 consecutive business days.
Second 180-day period follows initial non-compliance notice filed May 12, 2023.
CEO Lisa Conte notes Phase 3 OnTarget trial of Mytesi for chemotherapy-induced overactive bowel; top-line results expected before Thanksgiving 2023.
Investigator-initiated studies for MVID and SBS ongoing, results expected by end of 2023 and into 2024.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Jaguar Health, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 8, 2023, Jaguar Health, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until May 6, 2024, to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting the continued listing requirement for market value of publ

View on SEC.gov

1 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-115795

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.